Key Takeaways
- Mixed quarter, long-term conviction intact: Consolidated PAT rose 42% YoY to Rs. 1,782 crores, but BAGIC's combined ratio crossed 100 and BALIC's PAT fell 8% on new business strain. Management framed both as investment-phase outcomes consistent with a multi-decade build philosophy.
- BAGIC's underwriting discipline is being tested: The combined ratio hit 100.3% as motor and health inflation persisted, yet management insists corrective actions are working and the book is well-reserved. The bet is that giving up price-competitive business now protects returns later.
- BALIC is winning share but paying for it: Individual rated premium grew 22% (industry: 12%) and NBV jumped 38%, but PAT declined as new business strain rose. The growth engine is firing; the question is when profitability catches up.
- Retail health remains the open wound: Management admitted it does not yet see a clear profitability model for retail health, calling the industry's reliance on new-business profits unsustainable. BAGIC is rebuilding here but offered no timeline or targets.
- What to watch next quarter: Whether BAGIC's combined ratio improves as the corrective underwriting actions fully cycle through, any sign of price hardening in motor or health, and BALIC's progress on pushing term life mix higher.
General Insurance: Underwriting Stress & Philosophy
- Motor and health inflation drove the combined ratio up: Loss ratio rose to 72.1% from 69.6% YoY, with higher frequency in motor and health ex-COVID and persistent cost inflation. Management expects these headwinds to remain and is monitoring for further corrective action.
- Corrective actions are working, just slowly: Claim ratio improved sequentially by 2.4% in Q2 and 3.4% in Q3 as better business selection took hold. The lag is structural: the existing book continues to carry higher losses while the new, better-underwritten book builds, taking six to nine months to show.
- BAGIC walked away from price-competitive business: In larger cities where price competition intensified, BAGIC chose to give up motor business rather than chase unprofitable growth. Motor overall grew 6%, with two-wheeler up 24% but CV degrowing 5%.
- Commercial lines and group health are the bright spots: Commercial lines grew 14.9%, aided by a strong bancassurance network, multiline agency channel, and large reinsurance capacity. Group health grew over 40% and delivered a combined ratio below 100.
- The removal of IIB pricing caps is not a catastrophe: Management sees the shift as marginal: good risks may get better discounts, bad risks will remain priced similarly. Other reinsurers already had their own norms, so GIC's underwriting guidelines were never industry-wide.
- Reserving is conservative: The company is very well reserved, and despite strong reserving, the combined ratio remains among the best in the industry. Motor TP loss ratio at 82% is still high versus history, but management builds in margins for adverse deviation, inflation, and regulatory changes.
S. Sreenivasan: "In a market where most companies are reporting large underwriting losses, this result, we believe, displays BAGIC's commitment to a balanced and profitable growth on the back of strong underwriting and selection."
Life Insurance: Growth at a Cost
- BALIC is the second-fastest growing life insurer among the top 10 private players: Individual rated premium grew 22% vs the industry's 12%, and IRNB grew 38% in 9M FY23 vs the industry's 16%. Market share of IRNB among private players improved from 6.4% to 7.4%.
- NBV is growing faster than premium, for the fourth straight year: New Business Value net of expense overrun rose 38% to Rs. 210 crores in Q3 and 71% to Rs. 535 crores in 9M. The business has gone from negative margin after overruns to significantly positive.
- PAT fell 8% as new business strain bit: Higher growth in new business pushed up strain, partially offset by lower death claims. This is the tradeoff BALIC is making: invest in growth now, harvest profitability later.
- The product mix is balanced but term life lags: IRNB mix was par 19%, non-par savings 37%, ULIP 33%, annuity 7%, and term only 4%. Management acknowledged term life is a high-profit product where they could have done better and now have a defined focus on pushing its share higher.
- Bancassurance diversification is underway but will take time: BALIC has added IDFC First, City Union Bank, DBS, Punjab & Sind Bank, and J&K Bank over the last two years. These partners will take a year or two to build momentum. Axis Bank market share has been maintained and growth will now track the bank's own trajectory.
- Persistency is improving across vintages: 49th month persistency rose 4% to 63%, and 61st month improved 3% to 49%. Renewal premiums grew 30% in Q3, signaling a solid back-book.
S. Sreenivasan: "As we have mentioned before, BALIC's primary differentiator in the market is balance - a balance across products, a balance across distribution and a balance between growth and profitability."
Retail Health: The Unsolved Problem
- Management is candid about the profitability puzzle: Retail health does not generate float, and delivering superior ROE requires a combined ratio of 92-93%, which is not available in the market. The portfolio is also an aging one, meaning loss ratios worsen over time.
- Industry profits depend on new business, which is unsustainable: New books have lower loss ratios while old books run high. Companies growing aggressively on new business look profitable today, but third- and fourth-year books have combined ratios over 100. Management called this model explicitly unsustainable.
- BAGIC went slow on retail health during COVID and is now rebuilding: The company pulled back during the pandemic due to uncertainty and high losses. Price corrections in the market are not happening at the required speed. BAGIC's approach is agile: grow what looks good, slow down on what does not.
- No targets or roadmap were offered: Management declined to fix targets, saying they will not "just go for it without looking at how the market behaves." Distribution expansion to Tier 2/3 is underway as a consistent investment, but no quantum was disclosed.
Tapan Singhel: "If you look at across the industry, currently, the profit in the retail health portfolio comes from new business. So any company which is growing new business aggressively has a lower loss ratio, and the old book has a pretty high loss ratio. That to me is not a business which is sustainable."
Lending & Digital Businesses: Steady Contributors
- BFL delivered on all long-term guidance metrics: AUM grew to Rs. 2,30,842 crores, PAT rose 40% to Rs. 2,973 crores, and asset quality held strong with gross NPA at 1.14% and net NPA at 0.41%. New customers acquired: 0.31 crore in Q3, 0.85 crore in 9M.
- BHFL is growing profit even faster: AUM up 33% to Rs. 65,581 crores, PAT up 81% to Rs. 334 crores in Q3. Asset quality is pristine: GNPA 0.23%, NNPA 0.10%.
- Bajaj Markets is scaling: Attracted 84 lakh consumers, disbursed Rs. 1,175 crores in lending, sourced 62,000 cards. Total income nearly doubled to Rs. 104 crores from Rs. 56 crores a year ago.
- Bajaj Finserv Health is building a wellness ecosystem: 9.1 lakh health transactions, 9.74 lakh paying users, and 3.1 lakh users with renewable products. The Health Prime rider product crossed 10 lakh members. Total income rose to Rs. 45 crores from Rs. 28 crores. The focus is shifting from illness to wellness over the next two years.
Philosophy & Long-Term Positioning
- The company is built for centuries, not quarters: Management repeatedly emphasized a long-term philosophy, stating they are building a company for hundreds of years. Market behavior that is uncomfortable in the short term has no impact on their strategy.
- The underwriting cycle is a known, global phenomenon: Insurance globally follows cycles of high prices, then mounting losses, then hardening. In retail markets with new competitors, price competition is felt in easy-to-sell businesses. BAGIC's response is to look for alternatives and build the right skills, capabilities, and risk management.
- The choice is deliberate: profit over market share: Management framed the core question as whether to acquire customers knowing they will lose money, or write business where profit is visible. They choose the latter, even if it means slower growth in some lines.
- Commission deregulation is welcomed: Management sees it as a good move, arguing that different distribution channels require different commission levels and companies should decide within the expense of management limit. The new EoM guidelines also require that part of any reduction in expenses flows to the customer, not to distributors or the company.
S Sreenivasan: "The point is do we want to acquire customers knowing fully well that we will lose money, or do we want to write business where we see a visibility of profit?"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| BAGIC combined ratio | Target close to 100 for all lines of business | No date (ongoing obsession) |
| BALIC retail protection growth | Continue growing faster than peers; "bare minimum" expectation | Ongoing |
| BALIC term life mix | Defined focus on pushing percentage of term into total | No date |
| BALIC bancassurance diversification | Continue building more tie-ups; work in progress | Next few years |
| BAGIC dividend | Looking to increase dividends as they go along | No date |
| EBH wellness focus | Stronger focus on fitness, dietician, mental health; move from illness to wellness | Next two years |
| Quarterly EVOP walk disclosure | Will consider publishing from next year; will discuss internally | Possibly FY24 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Consolidated total income | ₹21,755 cr, 23% increase YoY |
| Consolidated profit after tax | ₹1,782 cr, 42% increase YoY |
| Core consolidated PAT (excl. MTM impact) | 34% increase YoY |
| BAGIC gross domestic premium income growth | 28.6%, vs private sector growth of 22.3% and industry growth of 18.5% |
| BAGIC combined ratio | 100.3%, vs 98.9% in Q3 FY22 |
| BAGIC loss ratio | 72.1%, vs 69.6% in Q3 FY22 |
| BAGIC profit after tax | ₹278 cr, vs ₹278 cr in Q3 FY22 (per an analyst's math) |
| BAGIC AUM | ₹25,977 cr, 8% growth for nine months ended 31st December 2022 |
| BALIC individual rated premium growth | 22%, vs industry 12% and private players 16% |
| BALIC new business value (net of expense overrun) | ₹210 cr, 38% growth from ₹152 cr in Q3 FY22 |
| BALIC profit after tax | ₹81 cr, de-growth of 8% from ₹88 cr in Q3 FY22 |
| BALIC IRNB mix | Par 19%, non-par savings 37%, term 4%, annuity 7%, ULIP 33% |
| BALIC 49th month persistency | 63%, improved by 4% YoY |
| BALIC 61st month persistency | 49%, improved by 3% YoY |
| BFL consolidated profit after tax | ₹2,973 cr, 40% higher than Q3 FY22 |
| BFL total AUM | ₹2,30,842 cr as of 31st December 2022, vs ₹1,81,250 cr a year ago |
| BFL gross NPA | 1.14% |
| BFL net NPA | 0.41% |
| BHFL AUM | ₹65,581 cr, 33% growth from ₹49,203 cr a year ago |
| BHFL profit after tax | ₹334 cr, 81% growth from ₹185 cr in Q3 FY22 |
| BHFL gross NPA | 0.23% |
| BHFL net NPA | 0.10% |
| Bajaj Markets total income | ₹104 cr, vs ₹56 cr in Q3 FY22 |
| Bajaj Finserv Health total income | ₹45 cr, vs ₹28 cr in Q3 FY22 |
| BAGIC solvency ratio | 373% |
| BALIC solvency ratio | 529% |